Cliff Asness's ABT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 1.16 M shares of Abbott Laboratories (ABT) worth $154.36 M, representing 0.10% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2013, adding 2.22 M shares. Largest reduction occurred in Q2 2016, reducing 2.49 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +2.15 M | Add 0.00% | 2.15 M | $65.50 |
| Q2 2013 | +4.37 M | Add 0.00% | 4.37 M | $34.88 |
| Q3 2013 | -145,668 | Reduce 3.33% | 4.23 M | $33.19 |
| Q4 2013 | +388,175 | Add 9.18% | 4.62 M | $38.33 |
| Q1 2014 | -1.78 M | Reduce 38.64% | 2.83 M | $38.51 |
| Q2 2014 | -805,281 | Reduce 28.43% | 2.03 M | $40.90 |
| Q3 2014 | -333,896 | Reduce 16.47% | 1.69 M | $41.59 |
| Q4 2014 | -126,057 | Reduce 7.44% | 1.57 M | $45.02 |
| Q1 2015 | -216,242 | Reduce 13.80% | 1.35 M | $46.33 |
| Q2 2015 | +337,306 | Add 24.96% | 1.69 M | $49.08 |
| Q3 2015 | +2.11 M | Add 125.06% | 3.8 M | $40.22 |
| Q4 2015 | +933,762 | Add 24.57% | 4.73 M | $44.91 |
| Q1 2016 | -670,146 | Reduce 14.16% | 4.06 M | $41.83 |
| Q2 2016 | -2.49 M | Reduce 61.39% | 1.57 M | $39.31 |
| Q3 2016 | -527,821 | Reduce 33.64% | 1.04 M | $42.29 |
| Q4 2016 | -867,261 | Reduce 83.30% | 173,914 | $38.41 |
| Q1 2017 | +460,477 | Add 264.77% | 634,391 | $44.41 |
| Q2 2017 | -509,318 | Reduce 80.28% | 125,073 | $48.61 |
| Q3 2017 | -31,757 | Reduce 25.39% | 93,316 | $53.36 |
| Q4 2017 | +317,078 | Add 339.79% | 410,394 | $57.07 |
| Q1 2018 | +114,895 | Add 28.00% | 525,289 | $59.92 |
| Q2 2018 | +422,853 | Add 80.50% | 948,142 | $60.99 |
| Q3 2018 | +286,021 | Add 30.17% | 1.23 M | $73.36 |
| Q4 2018 | +757,437 | Add 61.37% | 1.99 M | $72.33 |
| Q1 2019 | +46,449 | Add 2.33% | 2.04 M | $79.31 |
| Q2 2019 | +139,598 | Add 6.85% | 2.18 M | $83.76 |
| Q3 2019 | -750,271 | Reduce 34.45% | 1.43 M | $83.67 |
| Q4 2019 | -541,184 | Reduce 37.91% | 886,192 | $86.86 |
| Q1 2020 | -289,276 | Reduce 32.64% | 596,916 | $78.91 |
| Q2 2020 | +430,235 | Add 72.08% | 1.03 M | $88.81 |
| Q3 2020 | +277,685 | Add 27.03% | 1.3 M | $106.05 |
| Q4 2020 | +366,431 | Add 28.08% | 1.67 M | $108.25 |
| Q1 2021 | +638,726 | Add 38.22% | 2.31 M | $119.84 |
| Q2 2021 | -213,605 | Reduce 9.25% | 2.1 M | $115.73 |
| Q3 2021 | -104,884 | Reduce 5.00% | 1.99 M | $118.13 |
| Q4 2021 | -82,775 | Reduce 4.16% | 1.91 M | $140.74 |
| Q1 2022 | -25,868 | Reduce 1.36% | 1.88 M | $118.36 |
| Q2 2022 | -28,635 | Reduce 1.52% | 1.85 M | $107.99 |
| Q3 2022 | -182,643 | Reduce 9.85% | 1.67 M | $96.76 |
| Q4 2022 | +139,394 | Add 8.34% | 1.81 M | $109.43 |
| Q1 2023 | -162,069 | Reduce 8.95% | 1.65 M | $100.34 |
| Q2 2023 | -453,281 | Reduce 27.49% | 1.2 M | $108.25 |
| Q3 2023 | -113,358 | Reduce 9.48% | 1.08 M | $96.85 |
| Q4 2023 | -278,909 | Reduce 25.77% | 803,360 | $110.07 |
| Q1 2024 | +29,160 | Add 3.63% | 832,520 | $113.38 |
| Q2 2024 | +38,676 | Add 4.65% | 871,196 | $103.79 |
| Q3 2024 | +456,590 | Add 52.41% | 1.33 M | $112.82 |
| Q4 2024 | +166,342 | Add 12.53% | 1.49 M | $113.11 |
| Q1 2025 | +222,565 | Add 14.90% | 1.72 M | $132.30 |
| Q2 2025 | +147,176 | Add 8.57% | 1.86 M | $135.14 |
| Q3 2025 | -704,290 | Reduce 37.79% | 1.16 M | $133.12 |
Cliff Asness's Abbott Laboratories Investment FAQs
Cliff Asness first purchased Abbott Laboratories (ABT) in Q4 2012, acquiring 2,154,659 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Abbott Laboratories (ABT) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Abbott Laboratories (ABT) was in Q2 2013, adding 4,374,153 shares worth $152.57 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 1,159,579 shares of Abbott Laboratories (ABT), valued at approximately $154.36 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Abbott Laboratories (ABT) represents approximately 0.10% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Abbott Laboratories (ABT) was 4,733,740 shares, as reported at the end of Q4 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.